(Q33599906)

28 July 2017

title

Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis (English)

1 reference

28 July 2017

1 reference

Scott D Ramsey

1 reference

28 July 2017

Rahber Thariani

1 reference

28 July 2017

Norah Lynn Henry

1 reference

28 July 2017

David K Blough

1 reference

28 July 2017

Bill Barlow

1 reference

28 July 2017

Julie R Gralow

1 reference

28 July 2017

David L Veenstra

1 reference

28 July 2017

publication date

1 May 2013

1 reference

Journal of Comparative Effectiveness Research

28 July 2017

published in

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

28 July 2017

page(s)

325-334

1 reference

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Triple-negative breast cancer: clinical features and patterns of recurrence

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Tumor markers in breast cancer- European Group on Tumor Markers recommendations.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

A rational framework for decision making by the National Institute For Clinical Excellence (NICE).

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

The GIVIO trial on the impact of follow-up care on survival and quality of life in breast cancer patients. Interdisciplinary Group for Cancer Care Evaluation

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Clinical policies and the quality of clinical practice

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

Economic outcomes of breast cancer survivorship: CALGB study 79804.

28 July 2018

1 reference

Surveillance testing among survivors of early-stage breast cancer

21 January 2018

1 reference

Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer follow-up

21 January 2018

1 reference

Expected value of sample information calculations in medical decision modeling.

21 January 2018

1 reference

The value of value of information: best informing research design and prioritization using current methods.

21 January 2018

1 reference

Expected value of information and decision making in HTA.

21 January 2018

1 reference

The value of information and optimal clinical trial design.

21 January 2018

1 reference

The role of a pre-scored multi-attribute health classification measure in validating condition-specific health state descriptions.

21 January 2018

1 reference

Valuing temporary and chronic health states associated with breast screening.

21 January 2018

1 reference

Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication

21 January 2018

1 reference

Do oncologists believe new cancer drugs offer good value?

21 January 2018

1 reference

Follow-up of women with breast cancer: comparison between MRI and FDG PET.

21 January 2018

1 reference

Intensive vs Clinical Follow-up After Treatment of Primary Breast Cancer: 10-Year Update of a Randomized Trial

21 January 2018

1 reference

Tamoxifen for disease-negative but MCA-positive breast cancer patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4018420

What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?

30 October 2018

1 reference

12 December 2020

Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer

1 reference

12 December 2020

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease

1 reference

12 December 2020

Treatment of disease-negative but mucin-like carcinoma-associated antigen-positive breast cancer patients with tamoxifen: preliminary results of a prospective controlled randomized trial

1 reference

12 December 2020

Time and expected value of sample information wait for no patient

1 reference

12 December 2020

Evaluation of an intensive strategy for follow-up and surveillance of primary breast cancer

1 reference

12 December 2020

c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value

1 reference

12 December 2020

Tumour markers in breast cancer--EGTM recommendations. European Group on Tumor Markers

1 reference

12 December 2020

Possible Utility of Serum Determinations of CA 125 and CA 27.29 in Breast Cancer Management

1 reference

12 December 2020

Breast cancer recurrence diagnosis suspected on tumor marker rising: value of whole-body 18FDG-PET/CT imaging and impact on patient management

1 reference

12 December 2020

Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays

1 reference

12 December 2020

Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. The GIVIO Investigators

1 reference

12 December 2020

Practice patterns and guideline adherence of medical oncologists in managing patients with early breast cancer

1 reference

12 December 2020

C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients

1 reference

12 December 2020

The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies

1 reference

12 December 2020

Identifiers

DOI

10.2217/CER.13.15

1 reference

28 July 2017

1 reference

28 July 2017

1 reference